US private equity group Horizon Capital has made an undisclosed investment in marketing technology company Viseven, which serves the pharma and life sciences sectors.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Nataliya Andreychuk, CEO of Viseven, about her personal battle with breast cancer.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.